Christina Papini

Christina Papini

Auto-generated profile, based on publicly available information

Christina Papini

Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06520-8066

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2024 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
CPChristina Papini
Christina Papini
IUIrfan Ullah
Irfan Ullah
Amalendu Prakash RanjanAmalendu Prakash Ranjan
Amalendu Prakash Ranjan
SZShuo Zhang
Shuo Zhang
QWQihao Wu
Qihao Wu
KAKaren Anderson
Karen Anderson
As the SARS-CoV-2 virus continues to spread and mutate, it remains important to focus not only on preventing spread through vaccination but also on treating infection with direct-acting antivirals (DAA). The approval of Paxlovid, a SARS-CoV-2 main protease (Mpro) DAA, has been significant for treatment of patients. A limitation of this DAA, however, is that the antiviral component, nirmatrelvir, is rapidly metabolized and requires inclusion of a CYP450 3A4 metabolic inhibitor, ritonavir, to boost levels of the active drug. Serious drug–drug interactions can occur with Paxlovid for patients who are also taking other medications metabolized by CYP4503A4, particularly transplant or otherwise immunocompromised patients who are most at risk for SARS-CoV-2 infection and the development of severe symptoms. Developing an alternative antiviral with improved pharmacological properties is critical for treatment of these patients. By using a computational and structure-guided approach, we were able to optimize a 100 to 250 μM screening hit to a potent nanomolar inhibitor and lead compound, Mpro61. In this study, we further evaluate Mpro61 as a lead compound, starting with examination of its mode of binding to SARS-CoV-2 Mpro. In vitro pharmacological profiling established a lack of off-target effects, particularly CYP450 3A4 inhibition, as well as potential for synergy with the currently approved alternate antiviral, molnupiravir. Development and subsequent testing of a capsule formulation for oral dosing of Mpro61 in B6-K18-hACE2 mice demonstrated favorable pharmacological properties, efficacy, and synergy with molnupiravir, and complete recovery from subsequent challenge by SARS-CoV-2, establishing Mpro61 as a promising potential preclinical candidate.

2 September 2022 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
ZGZira T.K. Gannam
Zira T.K. Gannam
HJHaya Jamali
Haya Jamali
OKOh Sang Kweon
Oh Sang Kweon
JHJames Herrington
James Herrington
SSShanelle R. Shillingford
Shanelle R. Shillingford
KAKaren Anderson
Karen Anderson

30 January 2018 in Biophysical Reviews
Verified
Journal Article
Open access
PDF file
CPChristina Papini
Christina Papini
CRCatherine A. Royer
Catherine A. Royer
Biological function results from properly timed bio-molecular interactions that transduce external or internal signals, resulting in any number of cellular fates, including triggering of cell-state transitions (division, differentiation, transformation, apoptosis), metabolic homeostasis and adjustment to changing physical or nutritional environments, amongst many more. These bio-molecular interactions can be modulated by chemical modifications of proteins, nucleic acids, lipids and other small molecules. They can result in bio-molecular transport from one cellular compartment to the other and often trigger specific enzyme activities involved in bio-molecular synthesis, modification or degradation. Clearly, a mechanistic understanding of any given high level biological function requires a quantitative characterization of the principal bio-molecular interactions involved and how these may change dynamically. Such information can be obtained using fluctation analysis, in particular scanning number and brightness, and used to build and test mechanistic models of the functional network to define which characteristics are the most important for its regulation.

1 January 2022 in SSRN Electronic Journal
Verified
Preprint
Open access
PDF file
CPChristina Papini
Christina Papini
ZWZechen Wang
Zechen Wang
SKShalley N. Kudalkar
Shalley N. Kudalkar
TSTravis Parke Schrank
Travis Parke Schrank
TSTomoaki Sasaki
Tomoaki Sasaki
KAKaren S. Anderson
Karen S. Anderson
APOBEC3 family members are cytidine deaminases catalyzing conversion of cytidine to uracil. Many studies have established a link between APOBEC3 expression and cancer development and progression, especiallyAPOBEC3A (A3A) and APOBEC3B(A3B). Here, we explored the kinetic features of full length A3B and found that longer substrates and a purine at -2 position are more favored by A3B, whereas A3A) prefers shorter substrates and an adenine or thymine at -2 site. The clinical relevance of sequence preference of A3A and A3B was explored by a pan cancer bioinformatic analysis using TCGA and identified a correlation of A3A sequence preference at -2 position with APOBEC-related mutational signatures. We further revealed that endogenous A3B also possesses cytidine deaminase activity in human papilloma virus positive (HPV+) Head and Neck Cancer cells. Our study explored factors influencing the formation of A3A and A3B-related cancer mutations, which is essential for understanding APOBEC3-related carcinogenesis and facilitating drug discovery.